Compare IDEXX Laboratories, Inc. (IDXX) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Levi Strauss & Co. — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Levi Strauss & Co. trades at $24.55 (market cap $9.21B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.8× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.68% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LEVI | |
|---|---|---|
Market Cap | $44.48B | $9.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $24.99 |
52-Week Low | $520.87 | $17.92 |
Enterprise Value | $45.38B | $10.52B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Levi Strauss & Co. (LEVI) trades at $24.56, up 0.82% on the day, with strong analyst support (83% Buy rating) and a consensus price target of $28.00. Recent quarterly earnings have consistently beaten expectations, including a Q2 2026 EPS of $0.28 versus $0.24 expected, driven by robust direct-to-consumer growth. The company maintains solid profitability with a 61.72% gross margin and 9.66% net margin, while technical indicators show a bearish overall signal despite bullish moving averages.
The outlook is positive given earnings momentum and raised full-year guidance, though near-term stock performance faces headwinds from tariff concerns and foreign exchange pressures. Investment appeal lies in its digital strategy execution and dividend growth, with risks including competitive pressures and macroeconomic volatility affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
